BMEA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biomea Fusion Inc (BMEA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has some positive catalysts like a raised price target and upcoming data release, the company's weak financial performance, lack of recent news, and absence of strong trading signals make it prudent to hold off on investing right now.
The MACD is positive and expanding (0.0642), indicating bullish momentum. RSI is at 73.232, which is in the neutral zone. Moving averages are converging, suggesting indecision. The stock is trading near its resistance level (R1: 1.888), which may limit further upside in the short term.
Citi raised the price target from $6 to $7 and maintained a Buy rating. The firm also highlighted an 'upside 90-day catalyst watch' due to the upcoming Phase 1 GLP-131 study data release in Q2, which could increase investor interest.
The company's financial performance in Q4 2025 was weak, with net income dropping by -115.74% YoY and EPS declining by -107.41% YoY. Additionally, there is no recent news or significant insider/hedge fund activity to support a strong buy case.
In Q4 2025, the company reported no revenue growth (0% YoY). Net income dropped significantly by -115.74% YoY, and EPS declined by -107.41% YoY. Gross margin remained at 0%. Overall, the financials indicate poor performance.
Citi has a Buy rating on the stock and raised the price target to $7 from $6. The firm also expects increased investor interest due to upcoming data release in Q2.
